Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128.

Weidhaas JB, Li SX, Winter K, Ryu J, Jhingran A, Miller B, Dicker AP, Gaffney D.

Clin Cancer Res. 2009 Jun 15;15(12):4199-206. doi: 10.1158/1078-0432.CCR-08-2257. Epub 2009 Jun 9.

2.

Feasibility of RNA collection for micro-array gene expression analysis in the treatment of cervical carcinoma: a scientific correlate of RTOG C-0128.

Gaffney DK, Winter K, Fuhrman C, Flinner R, Greven K, Ryu J, Forbes A, Kerlin K, Nichols RC, Zempolich K.

Gynecol Oncol. 2005 May;97(2):607-11.

PMID:
15863167
3.

A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.

Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, Avizonis V, Fromm M, Greven K.

Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):104-9. Epub 2006 Nov 2.

PMID:
17084549
4.

Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.

Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, Avizonis V, Fromm M, Small W, Greven K.

Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):111-7. Epub 2007 May 4.

PMID:
17482376
5.

COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128.

Doll CM, Winter K, Gaffney DK, Ryu JK, Jhingran A, Dicker AP, Weidhaas JB, Miller BE, Magliocco AM.

Int J Gynecol Cancer. 2013 Jan;23(1):176-83. doi: 10.1097/IGC.0b013e3182791efc.

6.

Celecoxib treatment alters the gene expression profile of normal colonic mucosa.

Glebov OK, Rodriguez LM, Lynch P, Patterson S, Lynch H, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, Denobile J, Soballe P, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR.

Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1382-91.

7.

A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer.

Martínez-Monge R, Gaztañaga M, Aramendía JM, Cambeiro M, Arbea L, Espinós J, Aristu JJ, Jurado M.

Int J Gynecol Cancer. 2010 Jan;20(1):133-40. doi: 10.1111/IGC.0b013e3181c057ff.

PMID:
20130514
8.

A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.

Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD.

Clin Cancer Res. 2005 May 1;11(9):3342-8.

9.

A phase II trial with cisplatin-paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer.

Miglietta L, Franzone P, Centurioni MG, Boni L, Tacchini L, Cosso M, Boccardo F, Ferrarini M, Bruzzone M.

Oncology. 2006;70(1):19-24. Epub 2006 Jan 26.

PMID:
16439862
10.

Gene expression profiling to predict outcome after chemoradiation in head and neck cancer.

Pramana J, Van den Brekel MW, van Velthuysen ML, Wessels LF, Nuyten DS, Hofland I, Atsma D, Pimentel N, Hoebers FJ, Rasch CR, Begg AC.

Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1544-52. Epub 2007 Oct 10.

PMID:
17931799
11.

Changes in gene expression induced by chemoradiation in advanced cervical carcinoma: a microarray study of RTOG C-0128.

Zempolich K, Fuhrman C, Milash B, Flinner R, Greven K, Ryu J, Forbes A, Kerlin K, Nichols RC, Gaffney DK.

Gynecol Oncol. 2008 May;109(2):275-9. doi: 10.1016/j.ygyno.2008.01.027. Epub 2008 Mar 4.

PMID:
18299147
12.

Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.

Chung YL, Jian JJ, Cheng SH, Hsieh CI, Tan TD, Chang HJ, Hung CF, Horng CF, Soong T, Tsou MH.

Gynecol Oncol. 2005 Apr;97(1):126-35.

PMID:
15790448
13.

Cervical cancer: combined modality therapy.

Grigsby PW.

Cancer J. 2001 Jul-Aug;7 Suppl 1:S47-50. Review.

PMID:
11504285
14.

Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.

Dunst J, Haensgen G.

Strahlenther Onkol. 2001 Dec;177(12):635-40. Review.

PMID:
11789401
15.

Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the Radiation Therapy Oncology Group C-0116 trial.

Small W Jr; Radiation Therapy Oncology Group C-0116 trial.

Semin Oncol. 2003 Dec;30(6 Suppl 18):68-71.

PMID:
14727243
16.

Intra-arterial chemotherapy with cisplatin followed by radical radiotherapy for locally advanced cervical cancer.

Sueyama H, Nakano M, Sakumoto K, Toita T, Takizawa Y, Moromizato H, Kakihana Y, Kushi A, Moromizato H, Higashi M, et al.

Gynecol Oncol. 1995 Dec;59(3):327-32.

PMID:
8522249
17.

A microRNA expression signature for clinical response in locally advanced cervical cancer.

Pedroza-Torres A, Fernández-Retana J, Peralta-Zaragoza O, Jacobo-Herrera N, Cantú de Leon D, Cerna-Cortés JF, Lopez-Camarillo C, Pérez-Plasencia C.

Gynecol Oncol. 2016 Sep;142(3):557-65. doi: 10.1016/j.ygyno.2016.07.093. Epub 2016 Jul 14.

18.

Combined-modality therapy of locally advanced cervical cancer.

Rose PG.

J Clin Oncol. 2003 May 15;21(10 Suppl):211s-217s. Review.

PMID:
12743137
20.

Radiochemotherapy for patients with locally advanced cervical cancer: early results.

Ozsaran Z, Yalman D, Yürüt V, Aras A, Ozsaran A, Hanhan M, Haydaroğlu A.

Eur J Gynaecol Oncol. 2003;24(2):191-4.

PMID:
12701977

Supplemental Content

Support Center